{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361699996066039424.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1111/j.1600-0609.2004.00375.x"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1600-0609.2004.00375.x"}},{"identifier":{"@type":"URI","@value":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1600-0609.2004.00375.x"}}],"dc:title":[{"@value":"Hepatitis B virus reactivation and alemtuzumab therapy"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:p><jats:bold>Abstract: </jats:bold> Reactivation of hepatitis B virus infection in subjects receiving cytotoxic treatment for heamatological malignancies occurs in 21–53% of chronic HBsAg carriers and in an unknown number of HBsAg negative subjects harbouring occult HBV infection. Immunotherapy with alemtuzumab, a humanized monoclonal antibody against CD52 epitopes on lymphocytes cells produces deep immunosuppression. We describe two subjects with chronic lymphocytic leukaemia and occult HBV infection who developed a virological and biochemical flare of hepatitis B following immunotherapy with alemtuzumab. One of them developed full blown hepatitis with seroreversion from anti‐HBs to HBsAg after four weeks of alemtuzumab therapy. Lamivudine (100 mg die) achieved a complete clinical recovery and HBV‐DNA clearance from blood within 8 weeks. The second patient (HBsAg and HBV‐DNA seronegative, anti‐HBs and anti‐HBc positive before treatment) was kept under prophylaxis with lamivudine up to three months after alemtuzumab. Two months after withdrawal of lamivudine, clinical and laboratory features of acute hepatitis B developed. Lamivudine therapy was restarted and a prompt recovery was obtained with HBsAg and HBV‐DNA clearance.</jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381699996066039424","@type":"Researcher","foaf:name":[{"@value":"Emilio Iannitto"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699996066039428","@type":"Researcher","foaf:name":[{"@value":"Viviana Minardi"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699996066039425","@type":"Researcher","foaf:name":[{"@value":"Giuseppina Calvaruso"}]},{"@id":"https://cir.nii.ac.jp/crid/1380016866726733440","@type":"Researcher","foaf:name":[{"@value":"Antonino Mulè"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699996066039552","@type":"Researcher","foaf:name":[{"@value":"Emanuele Ammatuna"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699996066039429","@type":"Researcher","foaf:name":[{"@value":"Rosa D. Trapani"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699996066039430","@type":"Researcher","foaf:name":[{"@value":"Donatella Ferraro"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699996066039426","@type":"Researcher","foaf:name":[{"@value":"Vincenzo Abbadessa"}]},{"@id":"https://cir.nii.ac.jp/crid/1380016866726733441","@type":"Researcher","foaf:name":[{"@value":"Antonio Craxí"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699996066039431","@type":"Researcher","foaf:name":[{"@value":"Rosa D. Stefano"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"09024441"},{"@type":"EISSN","@value":"16000609"}],"prism:publicationName":[{"@value":"European Journal of Haematology"}],"dc:publisher":[{"@value":"Wiley"}],"prism:publicationDate":"2005-02-03","prism:volume":"74","prism:number":"3","prism:startingPage":"254","prism:endingPage":"258"},"reviewed":"false","dc:rights":["http://onlinelibrary.wiley.com/termsAndConditions#vor"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1600-0609.2004.00375.x"},{"@id":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1600-0609.2004.00375.x"}],"createdAt":"2005-02-03","modifiedAt":"2023-09-26","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567185479120640","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinical evaluation of a novel and highly sensitive immunoassay for anti‐hepatitis B core antigen using a fully automated immunochemical analyzer"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1391975276375902208","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Efficient Prophylactic Management of HBV Reactivation by an Information Technology Encoding System: Results of a 6-year Prospective Cohort Study"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1111/j.1600-0609.2004.00375.x"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.4445-20_references_DOI_JRTNftfw87j1TpuRRbSZVcVqRiV"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_JRTNftfw87j1TpuRRbSZVcVqRiV"},{"@type":"CROSSREF","@value":"10.1111/hepr.13229_references_DOI_JRTNftfw87j1TpuRRbSZVcVqRiV"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_JRTNftfw87j1TpuRRbSZVcVqRiV"}]}